FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Health & Nutrition News

Wheat Protein Better Than Whey Protein for Elderly Muscle Maintenance, Says Study

26 Aug 2016 --- A study from the University of Maastricht has proven that hydrolysed wheat protein is significantly more capable than whey protein when it comes to stimulating the muscle protein synthesis rates in the elderly.

Health & Nutrition News

Overall Weight Loss More Important Than Exercise Or Diet When It Comes To Heart Health

25 Aug 2016 --- New research has revealed that overall weight loss is the most important thing when it comes to cardiovascular health. Whether it’s achieved by diet, exercise or a combination of the two, is irrelevant.

Health & Nutrition News

High Protein Pasta Doesn’t Impact Satiety, According to Researchers

25 Aug 2016 --- Consumption of high protein or high fiber pasta doesn’t result in increased satiety over regular pasta, a new study shows.

Health & Nutrition News

Stepan Lipid Announce New Anchovy Based Omega 3 Supplement

25 Aug 2016 --- Stepan Lipid Nutrition, a global manufacturer of specialty lipids, has announced it will be showcasing their new omega 3 product, Marinol, at Supplyside West in October. 

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html